TCI Wealth Advisors’s Pliant Therapeutics PLRX Stock Holding History

TCI Wealth Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-51	Closed	-$1.36K	–	1672
2023 Q1	$1.36K	Buy	+51	New	+$1.45K	﹤0.01%	2057
2021 Q1	–	Sell	-21	Closed	–	–	2215
2020 Q4	$0	Hold	21	–	–	﹤0.01%	1632
2020 Q3	$0	Buy	+21	New	+$525	﹤0.01%	1633

Other funds holding PLRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

TCI Wealth Advisors's PLRX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 51 shares — an estimated $1.36K sold.

TCI Wealth Advisors first reported a position in PLRX in Q3 2020 and held it in 3 quarters. The position peaked at $1.36K in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

TCI Wealth Advisors reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 51 Pliant Therapeutics shares in Q2 2023, an estimated $1.36K.
TCI Wealth Advisors first reported a position in Pliant Therapeutics in Q3 2020 and held it in 3 quarters.
TCI Wealth Advisors's Pliant Therapeutics position peaked at $1.36K in Q1 2023.
144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.